Concepedia

Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study

Antoni Ribas, René González, Anna C. Pavlick, Omid Hamid, Thomas F. Gajewski, Adil Daud, Lawrence E. Flaherty, Theodore F. Logan, Bartosz Chmielowski, Karl D. Lewis,

The Lancet Oncology · 2014 · 295 citations · 23 references

DOI

Concepts

References

23

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text

, , +9

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Keith T. Flaherty, Igor Puzanov, Kevin B. Kim et al. · New England Journal of Medicine · 2010 · 3.5K citations

, , +17

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov et al. · The Lancet · 2012 · 3K citations

, , +11

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty, J. Infante, Adil Daud et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

, , +16

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text

, , +16